Inhibrx (INBX)
(Delayed Data from NSDQ)
$34.49 USD
+0.12 (0.35%)
Updated May 16, 2024 04:00 PM ET
After-Market: $34.51 +0.02 (0.06%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Inhibrx, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -241.36 | -145.23 | -81.77 | -76.12 | -51.40 |
Depreciation/Amortization & Depletion | 6.09 | 4.67 | 2.43 | 11.21 | 6.66 |
Net Change from Assets/Liabilities | 15.35 | 3.16 | -17.52 | 12.69 | 3.49 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 26.61 | 22.09 | 16.53 | 4.26 | 9.18 |
Net Cash From Operating Activities | -193.31 | -115.30 | -80.32 | -47.97 | -32.08 |
Property & Equipment | -4.59 | -0.69 | -0.81 | -1.36 | -1.81 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -4.59 | -0.69 | -0.81 | -1.36 | -1.81 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 202.32 | 2.76 | 3.96 | 136.88 | 12.00 |
Issuance (Repayment) of Debt | 0.00 | 128.86 | 39.99 | 41.36 | 33.81 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.36 | 126.93 | 39.82 | -11.78 | -2.48 |
Net Cash from Financing Activities | 201.96 | 258.55 | 83.77 | 166.46 | 43.33 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 4.06 | 142.56 | 2.64 | 117.12 | 9.44 |
Cash at Beginning of Period | 273.87 | 131.30 | 128.66 | 11.54 | 2.10 |
Cash at End of Period | 277.92 | 273.87 | 131.30 | 128.66 | 11.54 |
Diluted Net EPS | -5.12 | -3.62 | -2.15 | -3.01 | NA |
Fiscal Year End for Inhibrx, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -78.71 | -241.36 | -147.76 | -95.97 | -48.92 |
Depreciation/Amortization & Depletion | 1.60 | 6.09 | 4.55 | 3.00 | 1.49 |
Net Change from Assets/Liabilities | 7.20 | 15.35 | -13.01 | -2.03 | 1.42 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.86 | 26.61 | 19.73 | 12.76 | 6.07 |
Net Cash From Operating Activities | -63.05 | -193.31 | -136.49 | -82.24 | -39.94 |
Property & Equipment | -1.12 | -4.59 | -1.15 | -0.34 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -1.12 | -4.59 | -1.15 | -0.34 | -0.02 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 38.73 | 202.32 | 201.23 | 1.21 | 0.36 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.36 | -0.13 | 0.00 | 0.00 |
Net Cash from Financing Activities | 38.73 | 201.96 | 201.10 | 1.21 | 0.36 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -25.44 | 4.06 | 63.46 | -81.37 | -39.61 |
Cash at Beginning of Period | 277.92 | 273.87 | 273.87 | 273.87 | 273.87 |
Cash at End of Period | 252.48 | 277.92 | 337.33 | 192.49 | 234.25 |
Diluted Net EPS | -1.44 | -1.82 | -1.10 | -1.08 | -1.12 |